Testicular Cancer

We revealed unique molecular pathways in TGCT samples with cryptorchidism history and identified tumor-related features in cryptorchidism accumulation. Cryptorchidism history significantly remodels the immune microenvironment of TGCT.

P=N/A, N=201, Recruiting, University Medical Center Groningen

Key clinical translations include ERV-based stratification models predicting immune checkpoint inhibitor response in metastatic RCC, HERV-E-targeted adoptive T cell therapies, and noncoding RNA biomarkers for early bladder cancer detection. We further discuss unresolved mechanistic paradoxes such as contradictory prognostic associations between HERV superfamily expression and PBRM1 inactivation in RCC, concluding with priorities for future research: validating HERV-derived neoantigens in immunotherapy platforms, optimizing epigenetic priming strategies to enhance viral mimicry effects, and establishing standardized HERV signatures as clinical biomarkers through multi-institutional cohorts.

P1, N=10, Recruiting, West China Hospital | Not yet recruiting --> Recruiting

CBC-derived inflammatory markers and CRP represent promising, cost-effective, and easily accessible tools that complement classical tumor markers in testicular cancer. They offer both diagnostic and prognostic value, particularly in cases where traditional biomarkers are insufficient. Prospective multicenter studies are warranted to validate these findings and incorporate inflammatory indices into routine clinical algorithms for testicular cancer management.

BiTEs, such as pasotuxizumab for prostate cancer, and CD3×B7-H3 BiTE for bladder cancer, demonstrate potential in overcoming the limitations of traditional therapies and immune checkpoint inhibitors...Combination therapies with immune checkpoint inhibitors and oncolytic viruses, as well as advancements in BiTE technology, are essential to improving treatment efficacy. The future of BiTEs in uro-oncology lies in overcoming current limitations, optimising therapeutic strategies, and expanding clinical trials to solidify their role in cancer immunotherapy.

P1, N=72, Active, not recruiting, HiFiBiO Therapeutics | Recruiting --> Active, not recruiting | N=170 --> 72

The present study confirms that SCSTs classified as AGCTs differ from their ovarian counterparts in that they largely lack FOXL2 mutations.

Surgery preserving testicular tissue is recommended for bilateral benign teratomas to maintain fertility. Serial alpha-fetoprotein monitoring and ultrasound surveillance are essential postoperatively.

Post-pubertal YSTs are highly aggressive, and early detection and intervention are crucial for patients suspected of having cryptorchidism. Neoadjuvant chemotherapy can be considered as an adjuvant therapeutic strategy for reducing tumor burden in testicular tumors.

In addition, we found that NR6A1 can affect mTOR signaling, suggesting a broader role in tumor metabolism regulation. In summary, our data indicate that NR6A1 plays an oncogenic role by reprogramming glycolysis via the miR-302a/HK1 axis in lung adenocarcinoma.

Lastly, PFAS exposure altered the activity of PPARs, in TGCT cells, with the most prominent effects being antagonist activity toward PPARγ. These data support that PFAS may act as fatty acid mimics to modulate fatty acid metabolic and steroidogenic endocrine outcome leading to pro-cancer phenotypes in TGCTs.